Product Introduction:
Eurepa MF 1/500 mg Tablet combines two anti-diabetic agents: Repaglinide (1 mg) and Metformin (500 mg). Repaglinide stimulates the pancreas to release insulin after meals, while Metformin improves insulin sensitivity and reduces glucose production in the liver. Together, they help manage both fasting and postprandial blood sugar levels in patients with type 2 diabetes.
Uses:
-
Type 2 Diabetes Mellitus
-
Management of elevated fasting and post-meal blood glucose
-
Used when diet, exercise, and monotherapy are insufficient
Benefits:
-
Dual mechanism targets both insulin resistance and insulin secretion
-
Effective control of blood glucose spikes after meals
-
Reduces risk of long-term diabetes-related complications
-
Improves glycemic control
Composition:
-
Repaglinide – 1 mg
-
Metformin Hydrochloride – 500 mg
Side Effects:
-
Hypoglycemia (low blood sugar)
-
Nausea or vomiting
-
Diarrhea or stomach discomfort
-
Headache
-
Weight gain (rare)
Safety Advice:
-
Take with food to reduce stomach upset and prevent hypoglycemia
-
Not recommended in patients with severe kidney or liver impairment
-
Regularly monitor blood sugar levels
-
Avoid alcohol, which increases the risk of lactic acidosis
-
Do not skip meals while on this medication
-
Store in a dry, cool place, away from light and moisture
-
Keep out of reach of children
